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MEN-2 Syndrome: The Value of Screening and Central Registration; 
A Study of Six Kindreds in The Netherlands 
H.F.A. Vasen,* A.C. Nieuwenhuijzen Kruseman, A.M.J. Moers, C.J.M. Lips, 
E.K.M. Beukers, W.M. Wiersinga, and R.A. Geerdink 
Since 1975, six families with the MEN-2A syndrome including 66 patients have been identified in The 
Netherlands. All these patients underwent thyroidectomy for C-cell hyperplasia and/or medullary 
thyroid carcinoma (MTC); eight were symptomatic (Group A), 51 were relatives of patients found to be 
affected (Group B), and seven had had a negative screening test that became positive (Group C). To 
assess the effect of screening, we compared these groups with respect to the occurrence of metastatic 
MTC at thyroidectomy and the results ofthe postoperative calcitonin (CT) tests. We found that 87% of 
Group A, 37% of Group B; and none of Group C had metastatic disease at surgery. The "cure rates" 
in these three groups withMEN-2A, as determined by stimulated CT measurement, wasO%, 51%, and 
100%, respectively. From these results it may be concluded that screening can lead to the detection of 
MTC at an earlier stage which in turn could permit curative treatment and improvement of both 
prognosis and life expectancy. The need for supervision of affected families by central registration to 
guarantee the continuity of screening is stressed. (Henry Ford Hosp Med J 1987;35:101-3) 
The occurrence of medullary thyroid carcinoma (MTC) in combination with pheochromocytoma and hyper-
parathyroidism is a well-known hereditary syndrome (multiple 
endocrine neoplasia syndrome type 2A [MEN-2A] or Sipple's 
syndrome) characterized by autosomal dominant inheritance 
with a high degree of penetrance but varying expression (1-4). 
The only way to recognize patients with the MEN-2A 
syndrome at a curable stage is periodic examination of close rel-
atives of known patients (3,5-9). Potentially life-threatening 
tumors can be identified and removed at an early stage of devel-
opment (3,5-9). These advantages of periodic screening may 
counterbalance the disadvantages, which include psychological 
burden and violation of privacy. However, it has yet to be ascer-
tained whether or not large-scale screening of families with 
hereditary tumors meets the criteria for epidemiologic screening 
programs described by Wilson and Jungner in 1968 (10). Their 
most important criterion is that early treatment should improve 
prognosis and offer the prospect of prolonged life expectancy. 
In 1983 the Foundation for the Detection of Hereditary 
Tumors was established in The Netherlands. The objectives of 
this foundation include the promotion of early detection, the es-
tablishment and maintenance of a registration system, and the 
guarantee of continuity of screening programs (11). Since 1983 
the data on six families with the MEN-2A syndrome have been 
collected in the registration center, including 66 patients with 
MTC with or without pheochromocytomas. To assess the effect 
of screening on the prognosis, we reviewed the data from these 
families. Also the importance of central registration to guaran-
tee the continuity of screening is discussed. 
Materials and Methods 
Patients 
Clinical and genetic studies were performed in six kindreds 
with the MEN-2 A syndrome. 
To investigate the effect of screening we divided the patients 
into three groups. A, B, and C. Group A comprised patients 
who came for advice because they had symptoms caused by the 
MEN-2A syndrome (mainly probands). Group B was reserved 
for examined relatives of patients found to be affected (call-up 
group), and group C comprised patients with a previously nega-
tive screening test that became positive (converters). We com-
pared the occurrence of metastatic MTC at thyroidectomy in 
each group. Since the level of plasma calcitonin (CT) following 
postoperative provocative testing is probably the most sensitive 
indicator of curative thyroidectomy (9,12,13), we compared 
these groups with respect to the results of such testing. 
Screening program 
Screening programs applied in The Netherlands include a 
medical history, clinical examination, and measurement of 
calcium and phosphate levels in the first-degree relatives of 
patients. For the detection of MTC, the short calcium or 
pentagastrin infusion test is used. CT levels were determined 
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Table 1 
Pattern of Expression of the MEN-2 A Syndrome 
in 66 Patients 
Table 2 
Metastatic MTC at Diagnosis ofthe MEN-2A Syndrome: 
Postoperative Calcitonin Test Results 
Number of Cases 
Medullary thyroid carcinoma 
Medullary thyroid carcinoma -I- pheochromocytoma 
Medullary thyroid carcinoma -I- pheochromocytoma 
-I- hyperparathyroidism 
Medullary thyroid carcinoma -I- hyperparathyroidism 
43 
15 
6 
2 
by specific radioimmunoassay (4), For the detection of pheo-
chromocytoma, 24-hour urine was collected for estimation of 
adrenalin, noradrenalin, and their metabolites (4), The screen-
ing program in families with the MEN-2A syndrome starts be-
tween five and ten years of age and is continued on a yearly basis 
until the age of 35. After that age less frequent screening is suffi-
cient, ie, once every three years. 
When the value of CT after stimulation is more than three 
fimes the baseline value and exceeds 1,000 pg/mL, diffuse C-
cell hyperplasia or MTC is likely. In patients with an abnormal 
CT response in at least two separate provocative tests, surgery is 
indicated. The operation of choice for MTC is total thyroidec-
tomy with exploration of the central region of the neck. For the 
surgical treatment of pheochromocytoma, the bilateral extra-
peritoneal laterolumbar approach is used (14). 
National registry 
A registration center supervised by a multihospital committee 
was set up in The Netherlands in 1983 (11,15), This center is re-
sponsible for maintaining the continuity of the investigation 
by periodic assessment of the screening results. Annually, a 
reminder is sent to the physicians to screen the family members 
at risk. 
Because this project is concerned with registration of very 
sensitive data on large groups of patients and their families, 
much attention is paid to the protection of privacy. Persons to be 
registered have several rights: the right to refuse such registra-
tion, the right of access to their own data, and even the right to 
order destruction of such data. Furthermore, their data may not 
be given to third parties without their permission, A supervisory 
committee, composed of patients and persons with nonmedical 
backgrounds, was set up. Two genetic field workers (social 
workers with special training in genealogy) assist in the collec-
tion of data, the working out of pedigrees, and providing the 
relatives with information on request. In addition, pamphlets 
containing information about the objectives of the registra-
tion center and the syndrome itself were made available to 
the relatives. 
Results 
Since 1983 the data of 18 families with the MEN-2 syndrome 
were collected in the registration center. The data on six families 
with the MEN-2A syndrome are complete, including 66 pa-
tients, 32 men and 34 women. The pattem of expression of the 
disease is shown in Table 1. Six patients with MEN-2A had all 
three components of the syndrome, 15 had MTC and pheo-
chromocytoma, two had MTC and hyperparathyroidism, and 
the remaining 43 had only MTC. 
A 
Symptomatic 
GROUPS 
B 
Call-up 
C 
Converter 
Number of Cases (66) 8 51 7 
Average Age 41.7 29.4 13.4 
Metastatic MTC 87% 37% 0% 
Postoperative conversion of 
calcitonin tests to nonnal 
Basal 25% 70% 100% 
After stimulation 0% 51% 100% 
Sixty-six patients with abnormal test results had surgery, and 
thyroid abnormalities (MTC and/or C-cell hyperplasia) were 
confirmed in all of these. Seven of the eight patients in Group A, 
19 of the 51 patients in Group B, and none of the seven patients in 
Group C had metastatic disease at the time of thyroidectomy 
(Table 2). The basal CT value became normal in two of the eight 
patients in Group A, 36 of the 51 patients in Group B, and in 
each of the seven patients in Group C. The CT value after 
provocative testing became normal in none of the eight patients 
in Group A, 26 of the 51 patients in Group B, and in each of the 
seven patients in Group C. 
Discussion 
The best way to assess the effect of pjeriodic examination in fami-
lies with the MEN-2A syndrome would be to perform a 
randomized controlled trial. However, because there is substantial 
evidence in the literature for a favorable effect of treatment (3,5-9), 
this would seem to be excluded on ethical grounds. Another way to 
assess the effect of screening is to divide the patients into three 
groups—a symptomatic group (group A), a call-up group (group 
B). and a converter group (group C)—and compare them with 
respect to the stage of the thyroid tumor at surgery and the effect 
of surgery on the results of the postoperative CT test. 
We found that 87% of the symptomatic group, 37% of the call-up 
group, and none ofthe converters had metastatic MTC at the time of 
surgery. The "cure rates" in the three groups, as determined by 
stimulated CT measurement, were 0%, 51%, and 100%, 
respecfively. 
From these findings we concluded that screening led to detec-
tion of MTC at an earlier stage, which permitted curative treat-
ment and improvement of both prognosis and life expectancy. 
However, the ulfimate value of screening must be based on the 
long-term cumulafive experience with survival rates. We expect 
to find that the life expectancy of prospectively screened fami-
lies will not differ from that of the general population. 
The responsibility for the continuity of periodic examination 
is a heavy burden on the family physician or general intemist, 
and experience has shown that periodic control cannot be ade-
quately guaranteed in this way. Continuity was found to be inter-
rupted (for example, by completion of short-term research 
programs, loss of funding, departure or death of the coordinat-
ing physician, or moving away of the patients), which led to 
unnecessary morbidity and mortality. 
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One way to solve the practical problems involved might be to 
have the administrative work organized centrally and to have the 
family physician perform the main screening work. A study 
group was set up in 1981 to assess the feasibility of central regis-
tration and decentralized screening of large groups of patients 
with the MEN-2A syndrome and their relatives. To assure the 
continuity of this project, a foundation called Foundation for the 
Detection of Hereditary Tumors was established in 1983. After 
three years, our experience has shown that large groups of pa-
tients and their close relatives can be handled properly by the 
registration center and that the privacy of patients and relatives 
can be guaranteed. Patients and physicians have been generally 
enthusiastic about participating and extremely helpful with the 
family studies. At present, the activities of this foundation are 
limited to the MEN-2 syndromes and polyposis coli. Perhaps, if 
sensitive tests and curative treatment become available, other 
hereditary tumor syndromes could be included. 
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